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Abstract
Background: Whilst laterally wedged insoles, worn inside the shoes, are advocated as a simple,
inexpensive, non-toxic self-administered intervention for knee osteoarthritis (OA), there is
currently limited evidence to support their use. The aim of this randomised, double-blind
controlled trial is to determine whether laterally wedges insoles lead to greater improvements in
knee pain, physical function and health-related quality of life, and slower structural disease
progression as well as being more cost-effective, than control flat insoles in people with medial
knee OA.
Methods/Design: Two hundred participants with painful radiographic medial knee OA and varus
malalignment will be recruited from the community and randomly allocated to lateral wedge or
control insole groups using concealed allocation. Participants will be blinded as to which insole is
considered therapeutic. Blinded follow up assessment will be conducted at 12 months after
randomisation. The outcome measures are valid and reliable measures recommended for OA
clinical trials. Questionnaires will assess changes in pain, physical function and health-related quality-
of-life. Magnetic resonance imaging will measure changes in tibial cartilage volume. To evaluate
cost-effectiveness, participants will record the use of all health-related treatments in a log-book
returned to the assessor on a monthly basis. To test the effect of the intervention using an
intention-to-treat analysis, linear regression modelling will be applied adjusting for baseline
outcome values and other demographic characteristics.
Discussion: Results from this trial will contribute to the evidence regarding the effectiveness of
laterally wedged insoles for the management of medial knee OA.
Trial registration: ACTR12605000503628; NCT00415259.
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Osteoarthritis (OA) is a chronic, localised joint disease
affecting approximately one-third of adults, with the dis-
ease prevalence increasing with advancing age [1]. The
economic impact of knee OA is also a large and growing
problem for health care systems. In Australia, the esti-
mated financial costs of OA and other arthritic diseases in
2000 totalled almost 9 billion dollars [2]. Demographic
predictions indicate that people aged over 65 years will
comprise more than 20% of the population by 2040 [3],
thus knee OA will only become more prevalent.
The knee is the most common lower limb site for OA,
with the disease affecting the tibiofemoral and patel-
lofemoral joints either in isolation or combination. The
medial tibiofemoral compartment is the most commonly
affected (medial 67% versus lateral 16% [4]). Patients
with knee OA frequently report symptoms of knee pain
and difficulty with activities of daily living, such as walk-
ing, stair-climbing and housekeeping [5]. Ultimately, pain
and disability associated with the disease lead to a loss of
functional independence and a profound reduction in
quality-of-life.
Management strategies for knee OA may be regarded as
primary prevention (reduction of risk factors to reduce dis-
ease incidence); secondary prevention (interventions to
slow/prevent progression to serious disease) or; tertiary
prevention (treatment of pain and disability) [6]. To date,
most knee OA research has focussed on tertiary manage-
ment strategies, primarily drug therapies. Although effec-
tive, drug therapies have side effects and are expensive [7].
Accordingly, recent knee OA clinical guidelines reinforce
the importance of non-pharmacological strategies in the
management of the condition [8,9] yet there is an absence
of high quality evidence to support the use of such thera-
pies [8]. Thus there is a clear need for future clinical trials
to evaluate specific non-pharmacological therapies in
order to better guide clinical decision-making.
Given that there is currently no cure for knee OA and the
only established treatment for end-stage OA is costly joint
replacement, slowing of structural disease progression is
essential to help reduce the personal and societal burden
of knee OA. Traditionally, disease progression has been
assessed by measuring loss of joint space over time from
serial x-rays. There is now increasing use of magnetic res-
onance imaging to measure knee cartilage volume as it has
proved to be a valid and reproducible technique that is
more sensitive to change than x-rays [10]. Given the
absence of a sufficiently sensitive measure of structural
change until recently, this has meant that few interven-
tions have been tested as to their effect on disease progres-
sion.
Increased load across the joint is important in the patho-
genesis of knee OA. Interventions that alter knee load may
reduce symptoms and slow disease progression in
patients with knee OA. Direct measurement of knee joint
loads is not feasible because of the invasive nature of this
in vivo method. However, gait analysis can calculate exter-
nal joint-loading moments that are directly related to
internal joint loads. The external knee adduction moment
determines load distribution across the medial and lateral
tibial plateaus, with force across the medial compartment
almost 2.5 times that of the lateral [11]. This may explain
the much higher prevalence of medial compared with lat-
eral tibiofemoral joint OA.
The magnitude of the adduction moment is partly deter-
mined by the mechanical alignment of the knee. In
medial knee OA, mechanical alignment becomes varus as
the medial joint space narrows. Varus malalignment
causes the ground reaction force vector to pass more
medially to the knee joint centre, resulting in a higher
knee adduction moment. Cross-sectional studies demon-
strate that patients with knee OA have a higher knee
adduction moment during walking when compared to
healthy age-matched controls [12,13].
Recent research has found that a higher adduction
moment is associated with more severe knee pain [14]
and greater radiographic disease severity [15]. Severity of
knee malalignment is also significantly associated with
knee pain severity and physical function [16]. Longitudi-
nal studies have demonstrated that as little as a one-unit
increase in the adduction moment is associated with up to
a 6.5-fold increase in the risk of disease progression
[14,17]. Similarly, knee joint varus malalignment is also
correlated with disease progression [16,18,19]. Given the
importance of the knee adduction moment and joint
alignment with regard to both symptom severity and dis-
ease progression in knee OA, conservative strategies to
alter these biomechanical factors constitute a logical reha-
bilitative approach.
In 1987, Sasaki and Yasuda [20,21] first reported the
potential of a laterally wedged insole in the shoe to treat
medial knee OA. They demonstrated that the insole stati-
cally aligned the knee in a more upright position by shift-
ing the calcaneus into a valgus position relative to the
tibia. The authors concluded that such an alteration
helped reduce excessive loading of the medial joint sur-
face, leading to mitigation of knee pain. Biomechanical
studies have since evaluated the effects of laterally wedged
insoles on knee alignment and medial compartment load-
ing. Ogata et al [22] demonstrated that lateral thrust of the
knee (which forces the knee into varus alignment) was
reduced with lateral wedges in people with normal and
osteoarthritic knees. Similar results have been reported byPage 2 of 9
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onstrating that a 5° laterally wedged insole significantly
reduces the knee adduction moment by 6% in medial
knee OA. Finally, Giffin et al [26] observed a significant
varus to valgus shift in knee alignment on static radio-
graphs with a lateral heel wedge although this has not
been a consistent finding [27]. Thus there is evidence that
lateral wedges can reduce varus malalignment and the
adduction moment, two key biomechanical features that
are associated with knee OA symptoms and disease pro-
gression.
However, despite their biomechanical effects, few ran-
domised controlled trials have evaluated their clinical effi-
cacy [28-30]. In 156 patients with medial knee OA, no
significant effect of laterally wedged insoles on symptoms
over 2 years was demonstrated, as compared to control
insoles [28]. However, a significant reduction in non-ster-
oidal anti-inflammatory drug intake and greater compli-
ance was observed with laterally wedged insoles, leading
the authors to conclude that the results favoured a benefi-
cial effect of the intervention. A recent double-blind, ran-
domized, crossover trial in 90 patients found no effect of
6 weeks of lateral wedge use on pain or [30]. The samples
selected for these studies may partly explain the non-sig-
nificant effect of laterally wedged insoles. Whilst patients
demonstrated medial knee OA, selection criteria did not
consider knee joint alignment. Significant effects are more
likely in participants with evidence of varus malalign-
ment, rather than in a diverse cohort where alignment is
likely to range from valgus (in which lateral wedges could
be detrimental) to neutral to varus.
As previously stated, it is also important to evaluate the
effect of treatment on disease progression. Only one clin-
ical trial has investigated the effect of lateral wedges on
knee OA progression [29]. Using annual x-rays for two
years, this study failed to show that lateral wedges slowed
joint space narrowing over time compared to control
insoles. This non-significant finding may relate to the use
of relatively insensitive x-rays as a measure of disease pro-
gression, as well as to an inappropriate patient group and
the use of a short rather than full length wedge. Given the
paucity of data attesting to the structural effects of lateral
wedges over time, further research is necessary using more
sensitive methods of measuring disease progression such
as magnetic resonance imaging. Furthermore, no study to
date has evaluated the cost-effectiveness of lateral wedges.
The aim of this trial is to determine whether wearing lat-
eral wedge insoles for 12 months improves pain, physical
function and health-related quality of life, slows structural
disease progression and is more cost-effective than control
flat insoles in individuals with medial knee joint OA and
varus malalignment.
Methods/Design
Design
This will be a double-blind randomised controlled trial
(Figure 1). Potential participants will undergo telephone
screening followed by clinical examination by a physio-
therapist or medical practitioner and a podiatrist to ensure
they fulfil selection criteria. A screening x-ray will be per-
formed to assess knee joint alignment and disease sever-
ity. Eligible participants will then be stratified by disease
severity (Kellgren and Lawrence grade 2 and 3 [31] and
randomly allocated in permuted blocks of 6 to 12 to lat-
eral wedge or control flat insoles groups. The randomisa-
tion sequence will be generated a priori using the random
number function in Excel by an independent investigator
not directly involved in assessment of participants. Alloca-
tion will be sealed in opaque and consecutively numbered
envelopes held in a central location. These will be opened
Trial protocolFigure 1
Trial protocol.
12 months Final assessment
Monthly  Logbooks posted back to blinded assessor
Control flat
insoles
Lateral wedged
insoles
0 weeks   Consent, baseline assessment and
randomisation (n=200)
Ineligible
Fail inclusion criteria
Meet exclusion criteria
Xray and clinical
screening
Ineligible
Fail inclusion criteria
Meet exclusion criteria 
Telephone screeningPage 3 of 9
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recruitment and baseline testing of participants.
Participants
Two hundred men and women aged over 50 years will be
recruited from the community via advertisements in local
clubs, libraries, and the print and radio media in metro-
politan Melbourne, Australia. Eligibility will be confirmed
by radiographic and clinical examination. People with
tibiofemoral joint OA fulfilling American College of
Rheumatology classification criteria [32] and reporting
average knee pain on walking >3 on an 11-point scale will
be included. Other inclusion criteria will be: (i) knee
alignment ≤185° on a standardised semiflexed standing
posteroanterior knee x-ray (which corresponds to a
mechanical axis of ≤180° on a full leg xray indicating
varus malalignment) [33]; (ii) predominance of pain/ten-
derness over the medial region of the knee and; (iii)
medial radiographic OA defined as at least Grade 1 medial
joint space narrowing or Grade 1 medial tibial or femoral
osteophytes [34].
The exclusion criteria will include: (i) questionable or
advanced radiographic knee OA (Kellgren and Lawrence
stages 1 and 4 [31]); (ii) predominant patellofemoral
joint symptoms based on clinical examination; (iii) knee
surgery or intra-articular corticosteroid injection within 6
months; (iv) current or past (within 4 weeks) oral corti-
costeroid use; (v) systemic arthritic conditions; (vi) his-
tory of tibiofemoral/patellofemoral joint replacement or
tibial osteotomy; (vii) any other muscular, joint or neuro-
logical condition affecting lower limb function; (viii)
ankle/foot pathology or pain that precludes the use of
insoles; (ix) use of foot orthotics within past 6 months; (x)
regular use of footwear that does not accommodate an
insole; (xi) contraindications to magnetic resonance
imaging (eg. metal implant, cochlear implant, claustro-
phobia, pacemaker); (xii) planning to commence exercise
or other treatment for knee OA in the next 12 months;
(xiii) regular use of a gait aid and; (xiv) non-English
speaking.
Ethical approval has been obtained from the University of
Melbourne Human Research Ethics Committee (HREC
No. 050031) and from the Department of Human Serv-
ices Victoria, Radiation Safety Committee. All participants
will provide written informed consent.
Interventions
Participants will be informed that we are testing two dif-
ferent types of shoe insoles and will be blinded as to the
types of insoles or their perceived clinical effects. To
become accustomed to insole use over the first two weeks,
participants will commence with one hour per day there-
after increasing by one hour per day. Participants will be
asked to wear the insoles full time in their shoes. Insoles
will be replaced every four months.
Participants in the intervention group will be provided
with two pairs of bilateral standardised laterally wedged
(5°) insoles made of high density ethyl vinyl acetate (sim-
ilar to a running shoe midsole) wedged along the entire
lateral border of the foot (Foot Function Ltd, New Zea-
land). The 5° wedge has been selected because greater
wedging is unlikely to be tolerated by the wearer [24] and
would be difficult to accommodate within a normal shoe.
Participants in the control group will be provided with
two pairs of full length bilateral standardised footshaped
flat insoles made of low density ethyl vinyl acetate (Foot
Function Ltd, New Zealand). This is easily compressible
soft foam that will not alter foot mechanics.
Outcome assessment
Participants will be assessed at baseline and at 12 months
by an assessor blinded to group allocation. Outcome
measures have been selected based on those recom-
mended for clinical trials of knee OA [35,36]. In those
with bilateral knee OA, only the most symptomatic knee
will be assessed.
Age, gender, duration of knee OA symptoms, previous
treatment, surgery and medication use for knee OA will be
obtained by questionnaire. Radiographic disease severity
will be assessed from the baseline x-ray using the Kellgren
and Lawrence grading system [31]. Skyline knee x-rays
performed in nonweightbearing at 20° knee flexion will
also be obtained to assess severity of OA within the patel-
lofemoral joint. X-rays will be evaluated according to oste-
ophytes and joint space narrowing based on a 4 point
scale [34].
The primary outcomes will be knee pain and knee carti-
lage volume (Table 1). Average knee pain in the past week
will be self-assessed by an 11-point horizontal numeric
rating scale with terminal descriptors of zero = no pain
and 10 = worst pain possible. Such measurement has
demonstrated reliability in OA [35].
Knee cartilage volume will be measured using magnetic
resonance imaging (MRI). Knees will be imaged in a sag-
ittal plane on a 1.5-T whole-body magnetic resonance
unit (Signa Advantage HiSpeed GEMedical Systems, Mil-
waukee, WI, USA) using a commercial receive-only
extremity coil. The following sequence and parameters
will be used: a T1-weighted, fat-suppressed 3D gradient
recall acquisition in the steady state; flip angle 55 degrees;
repetition time 58 ms; echo time 12 ms; field of view 16
cm; 60 partitions; 512 (frequency direction, superior-infe-
rior) × 512 (phase encoding direction, anterior-posterior)Page 4 of 9
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images will be obtained at a partition thickness of 1.5 mm
and an in-plane resolution of 0.31 mm × 0.31 mm (512 ×
512 pixels) [37]. Knee cartilage volume will be deter-
mined by a blinded assessor analyzing baseline and final
MRI pairs. 3D image processing will be performed using
the software program OSIRIS (University of Geneva). In
this technique, the image data will be transferred to a
workstation and an isotropic voxel size will then be
obtained by a trilinear interpolation routine. The volume
of individual cartilage plates will be isolated from the total
volume by manually drawing disarticulation contours
around the cartilage boundaries on a section-by-section
basis. These data will then be resampled by means of
bilinear and cubic interpolation (area of 312 × 312 µm
and 1.5 mm thickness, continuous sections) for the final
3D rendering. The volume of the particular cartilage plate
will then be determined by summing all the pertinent
voxels within the resultant binary volume. The CV of this
method in our hands is 2% [37]. Knee cartilage volume
will be measured for both the medial and lateral tibial
compartments but the primary outcome will be the
change in medial tibial cartilage volume. Bone size is a sig-
nificant determinant of knee cartilage volume and thus a
potential confounder [38]. Medial and lateral tibial pla-
teaux areas as a measure of bone size will determined by
creating an isotropic volume from the sagittal, T1-
weighted fat saturation images, described above. This data
will be reformatted in the axial plane and the area directly
measured from these images as previously described [19].
The CV for the tibial plateau areas is 2.3% [19].
A number of secondary outcomes will be used (Table 1).
The Western Ontario and McMaster Universities
(WOMAC) Osteoarthritis Index is a disease-specific
instrument widely used in clinical trials, outcomes
research and epidemiological surveys. Its validity, reliabil-
ity and responsiveness have been demonstrated in an
extensive range of studies [39]. The WOMAC consists of
24 questions covering pain, stiffness and physical func-
tion. It provides a total score as well as scores for each sub-
scale.
The Assessment of Quality of Life (AQoL) instrument is
designed to measure health-related quality of life. It has
15 questions that cover five dimensions including illness,
independent living, social relationships, physical senses
and psychological wellbeing. The AQoL has strong psy-
chometric properties and is more responsive than other
widely-used scales including the Medical Outcomes Study
36-Item Short Form (SF-36) [40,41]. It produces a single
utility index that ranges from -0.04 (worst possible health-
related quality of life) to 1.00 (full health-related quality
of life). A clinically important difference in health related
quality of life can be defined as a change of 0.04 AQoL
units [42]. Population norms have been calculated for the
Australian population [42].
Table 1: Outcome measures
Primary Outcomes Measurement
Average pain in the past week 11 point horizontal numeric rating scale (end descriptors of 0 = no pain and 10 
= worst pain possible)
Medial tibial compartment cartilage volume Magnetic resonance imaging
Secondary Outcomes
Pain, stiffness and physical function in past 48 hours WOMAC Osteoarthritis Index – Likert version
Global perceived response to treatment for pain and for function Ordinal scale (1-much worse, 2-slightly worse, 3-no change, 4-slightly better, 
5-much better) at study completion
Health-related quality of life Assessment of Quality of Life index (AQol)
Physical activity levels • Physical Activity Scale for the Elderly (PASE)
• Pedometer worn twice for one week
Other measures
Compliance • Daily hours of use recorded in log-book
• 11 point horizontal numeric rating scale (end descriptors of 0 = not at all and 
10 = completely as instructed) at study completion
Discomfort with insoles • Assessed weekly in log-book on 5-point ordinal scale (1 = no discomfort, 2 = 
mild, 3 = moderate, 4 = severe, 5 = very severe discomfort)
• 11 point horizontal rating scale (end descriptors of 0 = extremely 
comfortable and 10 = extremely uncomfortable) at study completion
Other adverse effects Log-book and open probe questionningPage 5 of 9
(page number not for citation purposes)
BMC Musculoskeletal Disorders 2007, 8:96 http://www.biomedcentral.com/1471-2474/8/96Habitual physical activity will be measured in two ways,
one using a questionnaire and the second using a pedom-
eter. The Physical Activity Scale for the Elderly (PASE) will
be used to measure both the level and type of recreational
and occupational physical activity undertaken by partici-
pants over the previous week. The PASE was developed
and validated in samples of older adults (age 55+ years)
[43]. A pedometer (HJ-005 Omron Healthcare, Japan)
will be worn at the waist for a week on two occasions,
once at the beginning and once at the end of the 12-
month study to record the number of steps taken per day.
Participants will be asked to wear the pedometer full time
during their waking hours. Pedometers have been found
to be a simple and inexpensive means to estimate physical
activity levels [44,45]. It is recommended that at least
three days of sampling are needed to accurately assess
activity levels given differences between weekends and
weekdays [46].
Participants will rate their perceived change in pain and in
physical function with treatment (compared to baseline)
on an ordinal scale (1-much worse, 2-slightly worse, 3-no
change, 4-slightly better, 5-much better). Scales of this
kind are frequently used as an external criterion for com-
parison with changes in scores of other outcomes [47].
Measuring patient perceived improvement using a rating
of change scale has been shown to be a clinically relevant
and stable concept for interpreting truly meaningful
improvements from the individual perspective [48].
A number of other measures will be obtained (Table 1).
Participants will record compliance of and tolerance with
both types of insoles in a daily log-book. They will record
the number of hours per day of insole use. At the end of
the 12 months, participants will also indicate their per-
ceived compliance with the insoles using an 11 point hor-
izontal rating scale with terminal descriptors of zero = not
at all and 10 = completely as instructed. Discomfort with
the insoles will be evaluated weekly in the logbook on a
5-point ordinal scale (1 = no discomfort, 2 = mild, 3 =
moderate, 4 = severe, 5 = very severe discomfort) [28]. At
the end of the 12 months, participants will also rate their
overall level of discomfort of the insoles using an 11 point
horizontal rating scale with terminal descriptors of zero =
extremely comfortable and 10 = extremely uncomforta-
ble. Other adverse effects and the use of co-intervention
will be recorded in the log-book and by open-probe ques-
tioning by the assessor at trial completion. Log-books will
be posted back to the assessor on a monthly basis and
checked for completion.
Sample size calculations
Our sample size of 200 ensures adequate power for the
two principal endpoints of change in pain and change in
knee cartilage volume. Assuming that lateral wedges result
in a mean pain reduction of 2 on our numeric rating scale
(the minimum clinically important difference to be
detected in OA trials [49]), that control insoles have a
small placebo effect of 0.5 and that there is a SD of change
of 3 (based on our previous data evaluating conservative
OA interventions [50,51]), 170 participants would be
required in total to give 80% power (2 sided test, alpha =
0.05). We have previously demonstrated a reduction in
pain of this magnitude with knee taping [50] and physio-
therapy for knee OA [51].
The other major end point is rate of knee cartilage loss. We
have previously shown that the rate of tibial cartilage loss
is 5.3 +/- 5.2% per year in a cohort with knee OA [52]. We
categorized OA participants into tertiles: cartilage loss
<3% per annum, 3–8% per annum and > 8% per annum.
We found a linear increase in the risk of undergoing a
knee replacement within 4 years [53]. Participants who
lost cartilage at the rate of 3–8% per annum had a 2.4 fold
(0.4 to 12.2) increased risk of requiring a knee replace-
ment compared to participants who lost cartilage at the
rate of <3% per annum. Those with the highest rate of loss
of knee cartilage (>8% per annum) had a 7.1 fold (1.4 to
36.5) increased risk of requiring a knee replacement.
These data suggest that a clinically useful outcome with
lateral wedges would be to reduce the rate of knee carti-
lage loss to <3% per annum. With 100 subjects in each
arm of the study, we will have 80% power to show a dif-
ference between a 5.3 +/- 5.2% per year rate of cartilage
loss in the control group [52] and a <3% rate of cartilage
loss in the intervention group (2 sided test, alpha = 0.05).
This also takes into account a 20% drop-out rate.
Economic analysis
The economic analysis will be conducted from the per-
spective of the Australian health care system and the indi-
vidual patient. Participants will record visits to health care
providers (e.g. general practitioner, medical specialist,
other health care professionals), prescription and over the
counter medication, professional home care and hospital-
ization in a daily log-book. This will be completed and
returned to the assessor on a monthly basis. The log-book
will utilise a checklist format to minimize respondent bur-
den and ensure high quality data with minimal data loss.
Statistical analysis
A blinded statistician will analyse the data. All analyses
will be conducted on an intention-to-treat principle using
all randomized participants. Missing data will be replaced
by the last score carried forward. Demographic character-
istics and baseline data will be summarised by descriptive
statistics. For outcomes measured using an essentially
continuous scale, differences in mean change from base-
line to 12 months will be compared between groups using
linear regression modelling adjusting for baseline levels ofPage 6 of 9
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area, age and gender will also be included as covariates
[54,55]. Model assumptions will be checked by standard
diagnostic plots [56]. Participant measures of perceived
improvement following lateral wedges or flat insole treat-
ments will be compared by calculating the relative risks
and their 95% confidence intervals using log binomial
regression [57].
The primary economic evaluation will take the form of a
cost effectiveness study with a range of outcome measures
including the incremental cost per extra person with a
clinically significant improvement in pain, per extra per-
son perceived to be recovered, and per extra quality
adjusted life years (using the AQoL over 12 months). A
social perspective on costs will be taken that includes
resource use incurred both by health services and by the
participant irrespective of the source of payment. The
inclusion of time/productivity gains is controversial and
the cost effectiveness ratios will be calculated with and
without these indirect costs. All health care costs will be
included, however, to reduce the impact of extreme val-
ues, if inpatient hospital costs are unrelated to knee OA
they will be excluded. Standard methods of economic
evaluation alongside a clinical trial [58] will be used to
evaluate the differences in resource use and health out-
comes over 12 months between groups. The statistical
analysis of costs data will be similar to outcome data
although adjustments for overdispersion may be neces-
sary. Confidence intervals for incremental cost effective-
ness will be calculated directly using non-parametric
bootstrapping [59]. In addition we will calculate a cost
effectiveness acceptability curve based for a range of hypo-
thetical money values of outcomes [60]. This will be done
using individual cost and outcome data over the 12
months or, if adjustments for imbalance at baseline are
necessary, using regression analysis [61]. Hypothetical
money values will be taken from the decision making lit-
erature but the trial will also ask patients in each arm of
the trial their willingness to pay for the treatment prior to
and after treatment. This will not only provide money val-
ues for the calculation of net benefits but also provide evi-
dence on the influence of health experience on the value
of health outcome to patients.
Discussion
This study uses a double-blind randomised controlled
trial design to investigate whether lateral wedge insoles
have greater effects on symptoms and disease progression
and are more cost-effective than control flat insoles in
people with mild to moderately severe medial knee OA
and varus malalignment.
Recent research has highlighted the existence of sub-
groups of patients with knee OA particularly with regards
to local factors such as malalignment. It is known that
these subgroups show different risks of progression and
may respond differently to interventions [62]. Thus, our
inclusion/exclusion criteria aim to recruit a subgroup of
people with medial knee OA that would most likely
respond to lateral wedge insoles. We excluded those with
severe disease because there is little scope for structural
progression, one of our primary outcomes and recent
studies have also suggested that benefits with wedges
might be confined to those with mild to moderate disease
[63].
Lateral wedge insoles may vary in their angle of wedge and
in their length. Whilst a higher lateral wedge may produce
greater biomechanical effects, it is difficult to fit comfort-
ably inside the shoe. We are testing a full length wedge
rather than a heel wedge because we found that in 13 peo-
ple with medial knee OA, a full length wedge reduced the
knee adduction moment by 12% compared to no insoles
whereas moments obtained with rearfoot wedges were
not significantly different to those obtained without
insoles (Hinman et al unpublished data).
Our choice of outcome measures are those recommended
for use in clinical trials of OA by international rheumatol-
ogy bodies [35,36]. These include measures of pain, func-
tion, quality of life and global response to treatment.
Magnetic resonance imaging represents an advance in the
measurement of structural disease progression. Tradition-
ally, serial x-rays have been used to measure loss of joint
space over time. However, measuring joint space width
using conventional radiography provides only an approx-
imation of articular cartilage, while MRI directly visualizes
joint cartilage. MRI is recognised as a valid, accurate and
reproducible tool to measure articular cartilage volume
[38,64]. It is sensitive to change in both normal subjects
[65] and those with OA [52] and has been shown to relate
to clinically relevant end points including worsening of
knee symptoms [66] and the risk of knee replacement
[53].
It is anticipated that all participants will be recruited by
the end of 2007 with data acquisition completed a year
later. The results from this trial will contribute to evidence
based recommendations for the usefulness of lateral
wedged insoles in the management of medial knee OA.
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